LU88633I2 - Dorzolamide et ses sels pharmaceutiquement acceptables (Trusopt R) - Google Patents

Dorzolamide et ses sels pharmaceutiquement acceptables (Trusopt R)

Info

Publication number
LU88633I2
LU88633I2 LU88633C LU88633C LU88633I2 LU 88633 I2 LU88633 I2 LU 88633I2 LU 88633 C LU88633 C LU 88633C LU 88633 C LU88633 C LU 88633C LU 88633 I2 LU88633 I2 LU 88633I2
Authority
LU
Luxembourg
Prior art keywords
trusopt
dorzolamide
pharmaceutically acceptable
acceptable salts
treatment
Prior art date
Application number
LU88633C
Other languages
English (en)
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26747752&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU88633(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US07/067,326 external-priority patent/US4797413A/en
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of LU88633I2 publication Critical patent/LU88633I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/64—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/34—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Non-Silver Salt Photosensitive Materials And Non-Silver Salt Photography (AREA)
  • Lubricants (AREA)
  • Photosensitive Polymer And Photoresist Processing (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Dental Preparations (AREA)
  • Heat Sensitive Colour Forming Recording (AREA)
LU88633C 1987-06-26 1988-06-23 Dorzolamide et ses sels pharmaceutiquement acceptables (Trusopt R) LU88633I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/067,326 US4797413A (en) 1986-05-14 1987-06-26 Thieno thiopyran sulfonamide derivatives, pharmaceutical compositions and use
US07/208,314 US4863922A (en) 1984-12-12 1988-06-15 Substituted aromatic sulfonamides as antiglaucoma agents, compositions and use

Publications (1)

Publication Number Publication Date
LU88633I2 true LU88633I2 (fr) 1995-09-01

Family

ID=26747752

Family Applications (1)

Application Number Title Priority Date Filing Date
LU88633C LU88633I2 (fr) 1987-06-26 1988-06-23 Dorzolamide et ses sels pharmaceutiquement acceptables (Trusopt R)

Country Status (18)

Country Link
US (1) US4863922A (fr)
EP (1) EP0296879B1 (fr)
JP (1) JPH0631247B2 (fr)
AT (1) ATE86998T1 (fr)
AU (1) AU616664B2 (fr)
CA (2) CA1328262C (fr)
CY (1) CY1772A (fr)
DE (2) DE3879292T2 (fr)
DK (1) DK167684B1 (fr)
ES (1) ES2053738T4 (fr)
GR (1) GR3007407T3 (fr)
IE (1) IE62255B1 (fr)
IL (1) IL86822A (fr)
LU (1) LU88633I2 (fr)
NL (1) NL950006I2 (fr)
NZ (1) NZ225166A (fr)
PT (1) PT87832B (fr)
SG (1) SG24394G (fr)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1320487C (fr) * 1987-08-03 1993-07-20 George D. Hartman Thieno (2,3-.beta.)thiophen-2-sulfonamides utilises comme agents antig laucome
US5260453A (en) * 1988-09-23 1993-11-09 Ortho Pharmaceutical Corporation Substituted thienopyrans as antihypertensive agents
US4876271A (en) * 1988-12-20 1989-10-24 Merck & Co., Inc. Substituted thieno[3,2-b]thiophene-2-sulfonamides as topically active carbonic anhydrase inhibitors
US4929549A (en) * 1989-02-08 1990-05-29 Merck & Co., Inc. 5-carbamoylthieno[2,3-b]thiophene-2-sulfon-amides as topically active carbonic anhydrase inhibitors
US4946859A (en) * 1989-07-31 1990-08-07 Merck & Co., Inc. 4-(2-methyl-2-hydroxypropylamino)-5,6-dihydrothieno-[2,3-b]thiopyran-2-sulfonamide-7,7-dioxide
US5120757A (en) * 1989-07-31 1992-06-09 Merck & Co., Inc. Substituted aromatic sulfonamides as antiglaucoma agents
CA2028496A1 (fr) * 1989-10-31 1991-05-01 Tohru Nakao Composes de thiophene et leurs applications pharmaceutiques
JP3031498B2 (ja) * 1990-04-12 2000-04-10 メルク エンド カムパニー インコーポレーテッド 抗緑内障剤としての置換芳香族スルホンアミド類
IE911192A1 (en) * 1990-04-12 1991-10-23 Merck & Co Inc Substituted aromatic sulfonamides as antiglaucoma agents
US5045561A (en) * 1990-04-12 1991-09-03 Merck & Co., Inc. Substituted furan sulfonamides as antiglaucoma agents
US5157129A (en) * 1990-04-18 1992-10-20 Merck & Co., Inc. Enantiospecific synthesis of s-(+)-5,6-dihydro-4-(r-amino)-4h-thieno(2,3-b)thiopyran-2-sulfonamide-7,7-dioxide
US5091409A (en) * 1990-05-17 1992-02-25 Merck & Co., Inc. 4-alkylamino-6-(C3-5 -hydrocarbyl)thieno[2,3-B]thiopyran-2-sulfonamide-7,7-dioxides
US5093332A (en) * 1990-10-01 1992-03-03 Merck & Co., Inc. Substituted thieno(2,3-b)(1,4)thiazine-6-sulfonamides as antiglaucoma agents
EP0480745A3 (en) * 1990-10-12 1992-07-29 Merck & Co. Inc. Substituted dihydrothieno-thiophene-2-sulfonamides and dioxides thereof
US5216020A (en) * 1990-10-12 1993-06-01 Merck & Co., Inc. Substituted 4,5-dihydrothieno(2,3-b)thiophene-2-sulfonamides and 6,6-dioxides thereof
IL101537A (en) * 1991-04-17 1997-11-20 Merck & Co Inc OPHTHALMIC COMPOSITIONS COMPRISING COMBINATIONS OF A CARBONIC ANHYDRASE INHIBITOR AND A b-ADRENERGIC ANTAGONIST
SG84487A1 (en) 1991-04-17 2001-11-20 Merck & Co Inc Ophthalmic compositions comprising combinations of a carbonic anhydrase inhibitor and a b-adrenergic antagonist
JPH0830067B2 (ja) * 1991-10-15 1996-03-27 メルク エンド カムパニー インコーポレーテッド 三環チエノチオピラン類
US5932572A (en) * 1992-02-21 1999-08-03 Alcon Laboratories, Inc. Topical anti-glaucoma compositions
ATE169499T1 (de) * 1992-02-21 1998-08-15 Alcon Lab Inc Topische antiglaukoma zusammensetzungen, enthaltend karbonhydrasehemmer und beta-blocker
AU4729193A (en) * 1992-08-28 1994-03-29 Zeneca Limited Enzymatic asymmetric reduction process to produce 4 h-thieno(2,3-6)thio pyrane derivatives
JP3279671B2 (ja) * 1992-09-28 2002-04-30 鐘淵化学工業株式会社 チエノチオピラン誘導体の製造方法
TW265343B (fr) * 1993-03-22 1995-12-11 Merck & Co Inc
US6316443B1 (en) 1994-08-04 2001-11-13 Merck & Co., Inc. Ophthalmic compositions comprising combinations of a carbonic anhydrase inhibitor and a β-adrenergic antagonist
TWI238064B (en) * 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
FR2754712B1 (fr) 1996-10-17 1999-09-03 Merck Sharp Dohme Chibret Lab Compositions ophtalmiques
JP4000505B2 (ja) 1999-12-01 2007-10-31 第一三共株式会社 緑内障を治療するための併用剤
CA2396319A1 (fr) 2000-01-18 2001-07-26 Merck & Co., Inc. Compositions ophthalmiques pour traiter l'hypertension oculaire
US6548535B2 (en) * 2000-01-18 2003-04-15 Merck & Co., Inc. Method for treating ocular hypertension
ES2177415B1 (es) * 2000-09-04 2004-10-16 Ragactives, S.L. Procedimiento para la obtencion de 4-alquilamino-5, 6-dihidro-4h-tieno-(2,3b)-tiopiran-2-sulfonamida-7-dioxidos, e intermedios.
US20040254230A1 (en) * 2001-12-03 2004-12-16 Ogidigben Miller J. Method for treating ocular hypertension
US20050124595A1 (en) * 2002-03-15 2005-06-09 Goetz Michael A. Compositions and methods for treating glaucoma and ocular hypertension
WO2003103664A1 (fr) * 2002-06-06 2003-12-18 Merck Frosst Canada & Co. Derives d'imidazolidine-2-one disubstitues en 1,5 utiles en tant qu'agonistes du recepteur ep4 dans le traitement de troubles oculaires et de maladies osseuses
US20050256117A1 (en) * 2002-06-14 2005-11-17 Meng Hsin Chen Ophthalmic compositions for treating ocular hypertension
EP1515974A4 (fr) * 2002-06-17 2007-02-28 Merck & Co Inc Nouveaux bloqueurs de canaux maxi k, methodes d'utilisation et procedes de fabrication associes
EP1515730A4 (fr) * 2002-06-17 2005-07-20 Merck & Co Inc Nouveaux inhibiteurs de canaux maxi k, methodes d'utilisation et procede de fabrication associe
CA2488845A1 (fr) * 2002-06-17 2003-12-24 Merck & Co., Inc. Compositions ophtalmiques destinees a traiter l'hypertension oculaire
CA2495917A1 (fr) * 2002-08-28 2004-03-11 Merck Frosst Canada & Co. Derives de l'oxazolidin-2-one et de la thiazolidin-2-one antagonistes du recepteur ep4, pour le traitement du glaucome
JP2006505572A (ja) * 2002-10-25 2006-02-16 メルク フロスト カナダ アンド カンパニー Ｅｐ４受容体アゴニストとしての２−ピロリドン
CN1791402A (zh) * 2003-03-27 2006-06-21 麦克公司 治疗眼高压的眼科组合物
EP1828198B1 (fr) 2004-12-20 2011-02-09 SK Holdings Co., Ltd. Procede servant a separer des composes thiophenes optiquement purs en utilisant la chromatographie a lit mobile simule
MX2007007923A (es) * 2004-12-28 2007-11-14 Usv Ltd Procedimiento para preparar clorhidrato de 5,6-dihidro-4-(s)- (etilamino)-6-(s)metil-4h-tieno[2,3b]tiopiran-2-sulfonamida-7,7- dioxido.
US7109353B2 (en) * 2004-12-28 2006-09-19 Council Of Scientific And Industrial Research Process for preparing 5,6-dihydro-4-(S)-(ethylamino)-6-(S) methyl-4H-thieno[2,3b]thiopyran-2-sulphonamide-7,7-dioxide HCl
ATE438649T1 (de) * 2006-04-21 2009-08-15 Zach System Spa Verfahren zur herstellung von dorzolamid
EP1918293A1 (fr) * 2006-10-02 2008-05-07 Sandoz AG Procédé pour la préparation d'acide 4-oxo-thieno[2,3b]thiopyran-2-yl-sulfonique
AU2008220104B2 (en) 2007-02-28 2012-09-27 Asahi Kasei Pharma Corporation Sulfonamide derivative
KR20100031571A (ko) * 2007-05-07 2010-03-23 시플라 리미티드 도르졸라미드의 제조방법
WO2009105140A2 (fr) 2007-12-11 2009-08-27 Viamet Pharmaceuticals, Inc. Inhibiteurs de métalloenzymes utilisant des fractions de liaison à un métal en combinaison avec des fractions de ciblage
WO2010061398A1 (fr) * 2008-11-27 2010-06-03 Suven Life Sciences Limited Procédé pour la préparation de chlorhydrate de dorzolamide et ses intermédiaires
ES2543643T3 (es) 2011-03-10 2015-08-20 Zach System S.P.A. Proceso de reducción asimétrica
ITMI20121165A1 (it) * 2012-07-03 2014-01-04 Zach System Spa Processo di riduzione asimmetrica
CN103497202B (zh) * 2013-10-23 2015-12-02 武汉武药科技有限公司 盐酸多佐胺中间体的合成方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4416890A (en) * 1981-07-13 1983-11-22 Merck & Co., Inc. Benzothiazolesulfonamide derivatives for the topical treatment of elevated intraocular pressure
US4386098A (en) * 1981-11-03 1983-05-31 Merck & Co., Inc. 6-Hydroxy-2-benzothiazolesulfonamide for the topical treatment of elevated intraocular pressure
US4426388A (en) * 1982-04-02 1984-01-17 Merck & Co., Inc. 5-Benzothiazolesulfonamide derivatives for the topical treatment of elevated intraocular pressure
US4499103A (en) * 1983-03-17 1985-02-12 Merck & Co., Inc. Benzothiazole-2-sulfonamide derivatives for the topical treatment of elevated intraocular pressure
EP0189690B1 (fr) * 1984-12-12 1989-03-01 Merck & Co. Inc. Sulfonamides aromatiques substitués, leur préparation et compositions ophtalmiques les contenant
US4677115A (en) * 1984-12-12 1987-06-30 Merck & Co., Inc. Antiglaucoma thieno-thiopyran and thieno-thiepin sulfonamide derivatives, compositions, and method of use thereof
US4731368A (en) * 1986-12-08 1988-03-15 Merck & Co., Inc. Thienopyridine sulfonamides and their ophthalmological formulation

Also Published As

Publication number Publication date
DK348588D0 (da) 1988-06-24
ES2053738T3 (es) 1994-08-01
DE3879292T2 (de) 1993-09-09
DK348588A (da) 1989-02-24
CA1329211C (fr) 1994-05-03
ES2053738T4 (es) 2011-12-29
PT87832A (pt) 1989-05-31
AU1838788A (en) 1989-01-05
AU616664B2 (en) 1991-11-07
JPH01100174A (ja) 1989-04-18
GR3007407T3 (fr) 1993-07-30
DE19575017I2 (de) 2008-11-20
IE881933L (en) 1988-12-26
ATE86998T1 (de) 1993-04-15
NZ225166A (en) 1991-05-28
IL86822A0 (en) 1988-11-30
JPH0631247B2 (ja) 1994-04-27
SG24394G (en) 1994-06-10
DE3879292D1 (de) 1993-04-22
EP0296879A1 (fr) 1988-12-28
DK167684B1 (da) 1993-12-06
NL950006I1 (nl) 1995-06-16
IL86822A (en) 1992-01-15
NL950006I2 (nl) 1997-02-03
PT87832B (pt) 1992-10-30
EP0296879B1 (fr) 1993-03-17
CA1328262C (fr) 1994-04-05
US4863922A (en) 1989-09-05
CY1772A (en) 1995-10-20
IE62255B1 (en) 1995-01-11

Similar Documents

Publication Publication Date Title
LU88633I2 (fr) Dorzolamide et ses sels pharmaceutiquement acceptables (Trusopt R)
NL300098I1 (nl) Thiophene sulfonamides useful as carbonic anhydrase inhibitors.
IE853143L (en) Aromatic sulfonamides, antiglaucoma agents
DK154287D0 (da) Substituerede oxadiazol-derivater, fremgangsmaade til fremstilling deraf og mellemprodukter til brug ved fremgangsmaaden samt laegemiddel indeholdende oxadiazolerne
EP0594602A4 (fr) Inhibiteurs d'anhydrase carbonique du thiadiazole sulfonamide a activite topique oculaire.
NO893400L (no) Hiv protease inhibitorer egnet for behandling av aids.
LU88576I2 (fr) RISPERIDONE et ses sels pharmaceutiquement acceptables (Risperdal R)
DK429788D0 (da) Thieno(2,3-beta)thiophen-2-sulfonamid og farmaceutisk praeparat indeholdende en saadan forbindelse
DE69023459D1 (de) Behandlung von pulmonarer Disfunktion mit 15-Keto-prostaglandin-Derivaten.
ATE50257T1 (de) Kristalline form von benzothiazindioxydsalz.
IT8820050A0 (it) Metodo e apparecchiatura relativa per la produzione di una capsula trasparente.
IE892586L (en) Use of zofenopril for the treatment of rheumatoid arthritis
ES2085607T3 (es) Taco expansible de material sintetico.
IL86752A (en) Thiophene derivatives and their preparation and their use as intermediates in the preparation of n-(2,4-dimethylthien-3-yl) -n-(1-methoxyprop-2-yl) - chloroacetamide
ITRM910200A1 (it) Procedimento per la produzione di lenti oftalmiche a contatto.
NO894189D0 (no) 4-amino-3-acylkinolonderivater og deres anvendelse som inhibitorer av mavesyresekresjon.